NDAORALTABLET
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
FOSAMAX PLUS D (alendronate sodium and cholecalciferol) by Merck & Co.. Approved for vitamin d [epc]. First approved in 2005.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOSAMAX PLUS D is a fixed-dose combination of alendronate sodium (a bisphosphonate) and cholecalciferol (vitamin D3) administered orally as a tablet. It treats osteoporosis and vitamin D deficiency by inhibiting bone resorption and supplementing vitamin D levels. The combination addresses two key risk factors in bone health management simultaneously.
$0.604MPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with modest Medicare spending, signaling a mature asset with reduced team investment and focus shifting to generic transition planning.
Mechanism of Action
Pharmacologic Class:
Vitamin D
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
Started Jan 2003
10 enrolled
Osteoporosis
Career Relevance
Working on FOSAMAX PLUS D offers limited career growth due to its LOE-approaching lifecycle and minimal linked job openings. Roles focus on defensive commercial strategies, generic transition planning, and maintaining market share rather than launching or expanding the product.
Brand Manager
Worked on FOSAMAX PLUS D at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.